| Name | Title | Contact Details |
|---|---|---|
Melissa Cummings |
Executive Vice President, Chief Operating Officer | Profile |
Steven Leist |
Chief Technology Officer | Profile |
Caleb O'Connell |
Chief Information Security Officer | Profile |
BIND Biosciences, Inc. is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Blaze Bioscience, Inc. is a privately held biotechnology company focused on guided therapies. Blaze was founded in 2010 by Dr. Jim Olson, a pediatric neuro-oncologist at the Fred Hutchinson Cancer Research Center and Seattle Children`s Hospital, and Heather Franklin, a former senior business executive from ZymoGenetics. Blaze is working to develop Tumor Paint products and Optide*-based guided therapeutics.
Quva is a national provider specializing in health-system pharmacy services, focusing on sterile injectable compounding and advanced data software platforms. The company operates FDA-registered 503B outsourcing facilities that manufacture ready-to-administer compounded sterile pharmaceuticals, serving thousands of hospitals across the United States. Quva adheres to stringent cGMP standards and utilizes automation and integrated technologies to ensure a reliable supply of high-quality medications. Quvas operations are divided into two main divisions. Quva Pharma delivers essential sterile compounded medications, addressing supply chain reliability and medication shortages. Quva BrightStream offers a data analytics platform that aggregates and analyzes healthcare data, providing actionable insights to optimize pharmacy operations. The company emphasizes patient safety, transparent customer service, and a commitment to innovation and quality, making it a trusted partner for health systems and hospital pharmacies.
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using tablets that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary tablet vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart's development programs currently include tablet vaccines designed to protect against coronavirus, norovirus, seasonal influenza, and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart's first immuno-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.
Relay has developed a proprietary software solution for stakeholders of the biopharmaceutical technology licensing and development process.